Strota/ Newsroom/ 2026-09-04

WOCKPHARMA: Wockhardt swings to ₹106 crore profit in Q1 on 26% revenue growth as shares surged +7.1%

Strota Newsroom · session of 2026-09-04 · market close · WOCKPHARMA stock page →

Wockhardt Ltd. (WOCKPHARMA) surged +7.1% to ₹2,088.70 with 4 signals firing. Here is what the exchange data shows.

Wockhardt Ltd. closed 7.08% higher at ₹2,088.70 on 4 September, finishing at the top of a session that ranged between ₹1,976.10 and ₹2,108.50. The stock opened with a gap of 1.51% over the previous close of ₹1,950.60 and never gave it back, a gap-and-hold, where the opening premium survives the whole day instead of being sold into. With the Nifty up just 0.1%, almost all of the move was specific to the stock.

Volume did the talking. Strota's live-signals screen flagged an intraday volume spike of 11.8x, and relative volume for the session settled at 5.08, meaning turnover ran at roughly five times its recent norm. The stock also printed 1.44% above its volume-weighted average price and was sitting at the day's high when the last signals were logged, so buyers were paying up into the close rather than fading the rise.

The futures and options footprint is where the evidence goes blank. There is no F&O positioning data for Wockhardt in today's pack, so it is not possible to say whether the rise came with a long buildup, fresh futures positions opened as the price rose, or with shorts being squeezed out. No bulk or block deals were recorded today or over the past thirty days, and there were no insider filings in the last sixty days. Whatever drove the buying, it did not show up in the disclosed-deals tape.

Technically the stock was already on firm footing before today. It was trading above both its 50-day and 200-day moving averages, meets the trend-template criteria for a stock in an established uptrend, and today's session registered as a Darvas box breakout, a push through the top of its recent trading range. The 14-day RSI stood at 64.3, elevated but not extreme. The close leaves the share 13.77% below its 52-week high and 92.21% above its 52-week low. Over the past week it has added just over 5.6%, and over the past month roughly 5.7%, which, set against today's 7.08% jump, implies the preceding weeks were close to flat.

The news flow offered description more than explanation. A Business Standard headline from two hours before the close reported that Wockhardt had risen for a third straight session, and Univest carried stock-analysis items on the price streak over the previous two days, one of them citing a level of Rs 1,895.30. The most recent substantive headline is 25 days old: CNBC TV18 reported that Wockhardt swung to a ₹106 crore profit in the first quarter on 26% revenue growth. Older items describe a five-session losing streak and, about three months back, a 7% drop on profit-booking despite what Moneycontrol described as an upbeat outlook for its Zaynich antibiotic. Nothing among today's headlines pointed to a fresh announcement.

What the data establishes, then, is the shape of the move rather than its cause: a gap higher that held, turnover at several times normal, a close at the day's high, and a breakout from an existing uptrend. What it does not establish is a catalyst. There was no filing, no deal, no earnings event and no positioning data to explain why buyers turned up in such size. The data shows no single obvious catalyst.

The numbers

Signals that fired

Technical context

Volume ran at 5.1× its 20-day average; rsi(14) sits at 64; price is 13.8% from the 52-week high; trading above the 50-dma and 200-dma.

Recent headlines

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.